ClinicalTrials.gg
RecruitingNCT05849896Updated Sep 5, 2024

Clinical Relevance of the HD sEMG Signals in the Post-stroke Rehabilitation

An interventional study of Acquisition of HD sEMG signals using the WPM-SEMG device in Stroke, sponsored by Alain Kaelin. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Alain Kaelin · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 216 studies in Stroke with a site in Switzerland — 46 open to participants now, 60 under way, 6 of them phase 3. Stroke · Switzerland.

Planned enrollment
95th of 147
40 · median 79
Started
2023
with 8 others
No phase
95 of 216
24 open now
Primary completion
2026-02
later than 13 of 59 live
Registered
174th of 216
by date

Among the 216 studies in Stroke with a site in Switzerland, this one is the 95th largest by planned enrollment of the 147 interventional ones that give a count, is one of 9 that started in 2023, is one of 95 with no phase, reaches primary completion later than 13 of the 59 other live ones, and was the 174th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

46 of the 216 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Stroke with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the WPM-SEMG-V2 device (Wireless Portable and Multi-Channel, WPM) designated to acquire high-density (HD) surface electromyography (sEMG) signals in healthy volunteers and post-stroke patients. The main objectives are: 1) to technically and clinically validate the WPM-SEMG-V2 device in healthy volunteers; 2) to demonstrate the clinical relevance of the HD sEMG signals to support the process of rehabilitation of post-stroke patients. Participants will be asked to perform simple exercises using the muscles of the hand or the leg in static or dynamic contractions while wearing the WPM-SEMG-V2 device.

Read the detailed description

The participant will be instructed how to execute static or the dynamic exercises while wearing the WPM-SEMG-V2 device. The WPM-SEMG-V2 device will be initially tested in a small number of healthy volunteers to evaluate the technical and clinical performance of the device in different settings (i.e., static and dynamic muscle contractions). Preliminary information gathered in the first part of the investigation may eventually guide further device modifications. The second part will capture preliminary clinical performance of the device in post-stroke patients. The main aim is to study the behaviour of the neuromuscular system in voluntary muscle activations and demonstrate the clinical relevance of the HD sEMG signals to support the process of rehabilitation of post-stroke subjects.

03

Conditions studied

  • Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy volunteers

  • Written
  • Female or male
  • 18 years or older
  • Ability to understand the investigation
  • Willingness to complete all the investigation assessments
  • Ability to perform the procedures of the investigation
  • Ability to perform maximal voluntary muscle extension of the target muscle and limb

Additional inclusion criteria only for the recreationally active or athletic, healthy volunteers :

  • Subjects who participated in at least 150 min of moderate activity per week over the last six months.
  • between 18 and 20 years (preferably)

Post-stroke patients

  • Written informed consent
  • Female or male
  • 18 years or older
  • Have a first-time stroke
  • Ability to perform maximal voluntary muscle extension of the target muscle and limb
  • Preserved cognitive capacity to perform the task
  • Ability to understand the investigation
  • Willingness to complete all the investigation assessments
  • Ability to perform the procedures of the investigation

Exclusion criteria

Exclusion Criteria:

Healthy volunteers

  • Any significant acute disease state
  • Skin disorders/allergies at the site of contact with the device
  • History of skin disease
  • Known or allergy to component of the investigational product (e.g. metal alloys) or other materials used (e.g., abrasive gel, foam with polystyrene markers)
  • Chronic use of medications or treatment

Post-stroke patients

  • History of spinal cord injury or traumatic brain damage
  • Serious medical illness that precludes performing the task
  • Severe locomotion disorder due to other causes
  • Severe neurological disease other than stroke
  • Any significant acute disease state
  • Skin disorders/allergies at the site of contact with the investigational device
  • History of skin disease
  • Known hypersensitivity or allergy to component of the investigational product (e.g. metal alloys) or other materials used (e.g., abrasive gel, foam with polystyrene markers)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Static contractions in healthy volunteers

    Acquisition of HD SEMG signals of an upper limb muscle and a lower limb muscle while the participant executes simple static exercises.

    Device: Acquisition of HD sEMG signals using the WPM-SEMG device

  • Experimental
    Dynamic contractions in healthy volunteers

    Acquisition of HD SEMG signals of a leg muscle while the participant executes simple dynamic exercises.This arm will recruited recreationally active or athletic volunteers, preferably between 18 and 20 years

    Device: Acquisition of HD sEMG signals using the WPM-SEMG device

  • Experimental
    Static contractions in post-stroke patients

    Acquisition of HD SEMG signals of a lower limb muscle while the participant executes simple static exercises.

    Device: Acquisition of HD sEMG signals using the WPM-SEMG device

Interventions

  • DeviceAcquisition of HD sEMG signals using the WPM-SEMG device

    The WPM-SEMG-V2 device will be placed over the muscle of the participant to be investigated. A reference electrode over a bone close to the muscle of investigation will be applied. A sensor combing an accelerometer, gyroscope and magnetometer integrated in the WPM-SEMG-V2 device will be also used for the acquisition of body movement measures. An additional component for trapezoidal force measurement will be used during the acquisition in static contractions to measure the force. The participant will be instructed by the investigator how to execute the static or the dynamic exercises. Visual feedback will help the subject to track the trajectory.

06

What researchers measure

Primary outcomes

  1. Technical performance of the device (0 to 2)

    Assessed during signal acquisitions in static and/or dynamic contractions in healthy volunteers by checking the following parameters: 1. Interaction (0 or 1): when the WPM-SEMG-V2 is connected to the component for trapezoidal force measurement, both the sEMG signals and force data are recorded by the device on the device's SD card. 2. Availability (0 or 1): all data recordings are stored separately in the SD card. 3. Integrity of the final data (0 or 1): the recorded signals have the same duration of the recordings after post-processing of the data timestamp. The technical performance of the device is defined as Interaction\*(availability+integrity) in static contractions. The technical performance of the device is the sum of the scores for availability and integrity in dynamic contractions.

    Time frame: 1 day

  2. Quality of the WPM-SEMG-V2 device in the acquisition of HD sEMG signals (0 to 2)

    Assessed during signal acquisitions in static and/or dynamic contractions, both in healthy volunteers and post-stroke patients by measuring the following parameters: 1. Signal amplitude (0 or 1): the peak-to-peak sEMG signal amplitude is within the anatomical range of few-tens of µV to 2 mV. 2. Signal spectrum (0 or 1): the sEMG signal spectrum is within the anatomical range (sEMG power is mostly accounted for by the frequency components \< 350 Hz). Quality of the WPM-SEMG-V2 device in the acquisition of HD sEMG signals is the sum of the scores given to signal amplitude and signal spectrum.

    Time frame: 30 days

  3. Correlation between the properties of populations of Motor Unit (MU) with the type of the stroke.

    Assessed during signal acquisitions in static contractions in post-stroke patients. The following properties will be extracted from the MUs populations: discharge rate (pulses/seconds), recruitment threshold (percentage of the maximum voluntary force contraction), motor unit conduction velocity (meter/seconds), Muscle Fiber Conduction Velocity (meter/seconds. Type of stroke: acute or subacute.

    Time frame: 30 days

  4. Correlation between the properties of populations of Motor Unit (MU) with the severity of the stroke.

    Assessed during signal acquisitions in static contractions in post-stroke patients. The following properties will be extracted from the MUs populations: discharge rate (pulses/seconds), recruitment threshold (percentage of the maximum voluntary force contraction), motor unit conduction velocity (meter/seconds), Muscle Fiber Conduction Velocity (meter/seconds. The severity of the stroke will be measured by the National Institutes of Health Stroke Scale (score 0-42).

    Time frame: 30 days

  5. Correlation between the properties of populations of Motor Unit (MU) with the location of the stroke.

    Assessed during signal acquisitions in static contractions in post-stroke patients. The following properties will be extracted from the MUs populations: discharge rate (pulses/seconds), recruitment threshold (percentage of the maximum voluntary force contraction), motor unit conduction velocity (meter/seconds), Muscle Fiber Conduction Velocity (meter/seconds. The location of the stroke is obtained from MRI imaging (left hemispheric, right hemisferic, cortical, subcortical, brain stem).

    Time frame: 30 days

  6. Percentage of tracked MU

    Defined as the number of tracked MU / number of detected MUs in the baseline session, among the baseline, medium term, and long term sessions. Assessed during signal acquisitions in static contractions, both in healthy volunteers and post-stroke patients

    Time frame: 30 days

Secondary outcomes

  1. Incidence of serious and non-serious adverse event, adverse device effect, device deficiency and malfunction

    As assessed by reported adverse event.

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Feb 2026, 35 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 35 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2023
First posted
May 9, 2023
StartActual
Mar 13, 2023
Primary completionEst.
Feb 2026
CompletionEst.
Apr 2026
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05849896
Lead sponsor
Alain Kaelin
Collaborators
University of Applied Sciences and Arts of Southern Switzerland, Clinical Trial Unit Ente Ospedaliero Cantonale
Responsible party
Alain Kaelin (Principal investigator, Ente Ospedaliero Cantonale, Bellinzona) — Sponsor-investigator
First posted
May 9, 2023
Start date
Mar 13, 2023
Primary completion
Feb 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Sep 5, 2024

Study contacts

Alain Kaelin, Prof.
Contact
alain.kaelin@eoc.ch
+41 91 811 62 57
Alain Kaelin, Prof.
study director · Istituto di Neuroscienze Cliniche della Svizzera Italiana

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion